Back to the Future: How Biology and Technology Could Change the Role of PTFE Grafts in Vascular Access Management
Version of Record online: 22 AUG 2012
© 2012 Wiley Periodicals, Inc.
Seminars in Dialysis
Volume 25, Issue 5, pages 495–504, September/October 2012
How to Cite
Roy-Chaudhury, P., El-Khatib, M., Campos-Naciff, B., Wadehra, D., Ramani, K., Leesar, M., Mistry, M., Wang, Y., Chan, J.-S., Lee, T. and Munda, R. (2012), Back to the Future: How Biology and Technology Could Change the Role of PTFE Grafts in Vascular Access Management. Seminars in Dialysis, 25: 495–504. doi: 10.1111/j.1525-139X.2012.01091.x
- Issue online: 20 SEP 2012
- Version of Record online: 22 AUG 2012
Although the arteriovenous fistula (AVF) is the preferred mode of dialysis vascular access, AVF maturation failure remains a huge clinical problem, often resulting in a prolonged duration of use of tunneled dialysis catheters. In contrast, polytetrafluoroethylene (PTFE) grafts do not suffer from early failure, but have significant problems with later stenosis and thrombosis. This review will initially summarize the pathology and pathogenesis of PTFE graft dysfunction and will then use this as a basis for describing some novel therapies, which may have the potential to reduce PTFE graft dysfunction. Finally, we will emphasize that the introduction of such therapies could be an important first step toward individualizing overall vascular access care.